Urologic Cancer Treatments

Emory Healthcare Urology Services works with the Winship Cancer Institute of Emory University. We offer comprehensive treatments for cancers of the male and female urinary systems. Additionally, we help patients with urologic cancers of the male reproductive system.

These include:

• Bladder cancer
• Kidney cancer
• Penile cancer 
• Prostate cancer
• Testicular cancer

Access Leading-Edge Treatments via Clinical Trials

Clinical trials are an option for patients when deciding on urological cancer treatments. You may be able to access novel urologic cancer treatments. These treatments are often not yet available through standard practice.

In our clinical trials, specialists pioneer the world's most promising cancer treatments. We lead studies on new drugs, radiation therapy and surgical procedures.

Your care team will ensure you understand the known benefits and potential risks of any clinical trial. They will also explain the other treatment options available to you.

Access to clinical trials is available at all our Atlanta-area locations. To find out if you are eligible for a clinical trial, you can get detailed information from Winship Cancer Institute of Emory University.

The Emory Healthcare Difference in Urologic Cancer Care

As Georgia's first and only National Cancer Institute-designated Comprehensive Cancer Center, Winship Cancer Institute is at the forefront of cancer research, innovation and discovery. Our unique cancer care model places patients at the center of specialized care communities that bridge outpatient and inpatient care. Ranked among the top cancer programs in the nation by U.S. News & World Report, our cancer care teams integrate groundbreaking research into preventions and treatments to offer the best urologic cancer treatment plans for patients in Georgia and the Southeast. Drawing on Emory's vast resources in urologic oncology, radiation therapy, and medical oncology, our groundbreaking treatments for urologic cancer, including prostate, kidney, bladder and testicular cancers, produce better outcomes and are adopted by other leading cancer centers.